CBT
VRTX icon

Central Bank & Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Central Bank & Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$921K Buy
1,761
+1,251
+245% +$641K 0.13% 112
2026
Q2 		$253K Buy
+510
New +$226K 0.04% 171
2024
Q3 		– Sell
-40
Closed -$18.7K – 349
2024
Q2 		$18.7K Hold
40
– – ﹤0.01% 292
2024
Q1 		$16.7K Sell
40
-58
-59% -$24.5K ﹤0.01% 276
2023
Q4 		$39.9K Sell
98
-16
-14% -$5.91K 0.01% 253
2023
Q3 		$39.6K Hold
114
– – 0.01% 237
2023
Q2 		$40.1K Sell
114
-27
-19% -$9.1K 0.01% 233
2023
Q1 		$44.4K Buy
141
+109
+341% +$32.7K 0.01% 231
2022
Q4 		$9.24K Hold
32
– – ﹤0.01% 291
2022
Q3 		$9K Sell
32
-133
-81% -$38.3K ﹤0.01% 282
2022
Q2 		$46K Sell
165
-80
-33% -$21.4K 0.01% 228
2022
Q1 		$64K Buy
245
+165
+206% +$39.2K 0.01% 218
2021
Q4 		$18K Sell
80
-1,244
-94% -$242K ﹤0.01% 267
2021
Q3 		$240K Buy
1,324
+25
+2% +$4.88K 0.04% 152
2021
Q2 		$262K Buy
1,299
+56
+5% +$11.7K 0.04% 149
2021
Q1 		$267K Buy
1,243
+70
+6% +$15.4K 0.05% 144
2020
Q4 		$277K Buy
1,173
+702
+149% +$161K 0.05% 135
2020
Q3 		$128K Buy
471
+420
+824% +$116K 0.02% 162
2020
Q2 		$15K Hold
51
– – ﹤0.01% 214
2020
Q1 		$12K Buy
+51
New +$11.7K ﹤0.01% 220
2019
Q2 		– Sell
-24
Closed -$4K – 280
2019
Q1 		$4K Hold
24
– – ﹤0.01% 257
2018
Q4 		$4K Hold
24
– – ﹤0.01% 255
2018
Q3 		$5K Buy
+24
New +$4.27K ﹤0.01% 252
2016
Q2 		– Sell
-119
Closed -$9K – 345
2016
Q1 		$9K Hold
119
– – ﹤0.01% 278
2015
Q4 		$15K Buy
119
+85
+250% +$10.3K ﹤0.01% 261
2015
Q3 		$4K Hold
34
– – ﹤0.01% 351
2015
Q2 		$4K Buy
34
+7
+26% +$882 ﹤0.01% 338
2015
Q1 		$3K Buy
+27
New +$3.24K ﹤0.01% 313

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Central Bank & Trust's VRTX Position: Q3 2026 in Review

Central Bank & Trust increased its Vertex Pharmaceuticals (VRTX) stake by 245% in Q3 2026, buying an estimated $641K and bringing the position to 1,761 shares worth $921K. The position accounts for 0.13% of the portfolio, ranked #112.

Central Bank & Trust first reported a position in VRTX in Q1 2015 and has held it in 28 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Central Bank & Trust held 1,761 shares of Vertex Pharmaceuticals worth $921K as of Q3 2026.
  • Central Bank & Trust bought 1,251 Vertex Pharmaceuticals shares in Q3 2026, an estimated $641K.
  • Vertex Pharmaceuticals made up 0.13% of Central Bank & Trust's portfolio in Q3 2026, its #112 holding.
  • Central Bank & Trust first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 28 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Central Bank & Trust's 13F filing for Q3 2026, filed 9 Oct 2026.